Cancer Gene Therapy Market Benefits, Opportunities and Future Investments Forecast To 2024

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade.

Delaware, Selbyville - June 13, 2019 /MarketersMedia/ —

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.

Request a sample of this premium report titled at https://www.marketstudyreport.com/request-a-sample/467801/?utm_source=MM-VHS

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.

Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.

Key insights from the report include:

U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

Request a discount on standard prices of this premium report titled at https://www.marketstudyreport.com/check-for-discount/467801/?utm_source=MM-VHS

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.
China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.
The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Report Content
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources
Chapter 2. Executive Summary
2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends
Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter's analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis
Chapter 4. Cancer Gene Therapy Insights
4.1. Cancer gene therapy market share by therapy, 2015 & 2024
4.2. Gene Induced Immunotherapy
4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.2. Delivery of cytokine gene
4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.3. Delivery of tumor antigen gene
4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3. Oncolytic Virotherapy
4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.2. Adenoviruses
4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.3. Lentiviruses
4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.4. Retrovirus
4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.5. Adeno Associated Virus
4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.6. Herpes Simplex Virus
4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.7. Alphavirus
4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.8. Vaccinia Virus
4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.9. Simian Virus
4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.10. Others
4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4. Gene transfer/ Gene replacement
4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.2. Naked/Plasmid Vectors
4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.3. Electroporation
4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.4. Sonoportion
4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.5. Magnetofection
4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.6. Gene Gun
4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)

Complete report titled at https://www.marketstudyreport.com/reports/cancer-gene-therapy-market

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com/

Source URL: https://marketersmedia.com/cancer-gene-therapy-market-benefits-opportunities-and-future-investments-forecast-to-2024/524003

Source: MarketersMedia

Release ID: 524003

More Press Releases

APNewsBreak: California launches anti-illegal pot campaign

Jun 25, 2019

LOS ANGELES — Marijuana shoppers are going to be getting a message from California regulators: Go legal. Aiming to slow illegal pot sales that are undercutting the nation's largest licensed market, California is kicking off a public information campaign — Get #weedwise — that encourages consumers to verify that their purchases are tested and legal. Ads will be hitting social media sites and billboards promoting a state website where shoppers can quickly check if a shop is licensed — CApotcheck.com. The advertising campaign makes a simple argument: You don't know what you're getting if you buy illegal products. One ad...

Q&A: How can stocks cheer while bonds can't find a friend?

Jun 25, 2019

NEW YORK — Why is the stock market so happy and the bond market so gloomy? Just as the S&P 500 was setting a record high Thursday, bond yields were tumbling to their lowest levels since Donald Trump was elected. The yield on the 10-year Treasury, which influences rates for mortgages and other loans, dropped below 2% at one point. It was above 3.20% in November. Usually, stock prices rise when investors are feeling confident. Bond yields, meanwhile, often fall when investors are worried about a softening economy. How can both be happening at the same time? In large part,...

Energy stocks swing with economic signals, Mideast tensions

Jun 25, 2019

NEW YORK — Energy stocks have gone along with oil prices on a wild ride this quarter. Oil prices steadily rose through April and then sank as the trade war between the U.S. and China escalated and threatened global economic growth. More recently, rising tensions between the U.S. and Iran have pushed prices higher. After hitting a high for the year of $66.30 a barrel in late April, oil dropped about 22% through early June as global demand weakened and investors grew increasingly worried about economic growth. Even with the geopolitical tensions of the past week, that gloomy backdrop remains...

Asian shares gain, Shanghai up 2.4%, on Fed rate cut talk

Jun 25, 2019

BANGKOK — Asian shares are higher with the Shanghai benchmark up 2.4% on hopes that a meeting between President Donald Trump and his counterpart Xi Jinping next week might help ease trade tensions. The Thursday tracked modest gains on Wall Street. Tokyo's Nikkei 225 index added 0.6% to 21,462.86 while the Hang Seng in Hong Kong surged 1.2% to 28,545.23. Shanghai was up 2.4% to 2,987.12 while Australia's S&P ASX 200 picked up 0.6% to 6,687.40. India's Sensex advanced 0.4% to 39,277.17. Shares fell in Jakarta but rose slightly in Taiwan and elsewhere in Southeast Asia. Confirmation that Trump and...

White House offers budget freeze if Dems don't agree to deal

Jun 25, 2019

WASHINGTON — Trump administration bargainers offered a one-year budget freeze and said Democratic spending demands remained too high as talks with congressional leaders aimed at averting deep cuts in defense and domestic programs this autumn seemed no closer to resolution. Emerging from a session in House Speaker Nancy Pelosi's office that lasted over an hour, Treasury Secretary Steven Mnuchin said that without an agreement, the White House was prepared to live with a one-year extension of this year's budget. That would prevent an enormous $125 billion in automatic cuts to defense and domestic programs that would otherwise be triggered by...

Subscribe to our newsletter!

Your Name

Your Email Address